Jazz Pharmaceuticals plc – (JAZZ) Stock Rating Upgraded by Janney Montgomery Scott

Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) was upgraded by investment analysts at Janney Montgomery Scott from a “neutral” rating to a “buy” rating in a report released on Thursday. The firm currently has a $175.00 price target on the specialty pharmaceutical company’s stock, up from their prior price target of $138.00. Janney Montgomery Scott’s price objective would suggest a potential upside of 14.50% from the stock’s previous close.

JAZZ has been the subject of a number of other reports. Cantor Fitzgerald reissued a “buy” rating and issued a $187.00 price target on shares of Jazz Pharmaceuticals plc – in a report on Thursday, January 12th. Zacks Investment Research cut Jazz Pharmaceuticals plc – from a “hold” rating to a “sell” rating in a report on Thursday, March 2nd. Guggenheim reissued a “buy” rating and issued a $200.00 price target on shares of Jazz Pharmaceuticals plc – in a report on Thursday, February 9th. Deutsche Bank AG set a $148.00 price target on Jazz Pharmaceuticals plc – and gave the stock a “buy” rating in a report on Wednesday, February 8th. Finally, BMO Capital Markets reissued an “outperform” rating and issued a $192.00 price target on shares of Jazz Pharmaceuticals plc – in a report on Thursday, January 12th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and fourteen have issued a buy rating to the company’s stock. Jazz Pharmaceuticals plc – presently has an average rating of “Buy” and a consensus target price of $181.23.

Analyst Recommendations for Jazz Pharmaceuticals plc - (NASDAQ:JAZZ)

Shares of Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) traded down 0.89% during mid-day trading on Thursday, hitting $152.84. 436,725 shares of the stock were exchanged. Jazz Pharmaceuticals plc – has a 12 month low of $95.80 and a 12 month high of $160.00. The stock’s 50 day moving average is $143.48 and its 200-day moving average is $123.54. The stock has a market cap of $9.13 billion, a PE ratio of 23.84 and a beta of 1.22.

Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) last released its quarterly earnings results on Tuesday, February 28th. The specialty pharmaceutical company reported $1.91 earnings per share for the quarter, missing the Zacks’ consensus estimate of $2.65 by $0.74. Jazz Pharmaceuticals plc – had a return on equity of 30.50% and a net margin of 24.81%. The company earned $396.62 million during the quarter, compared to analyst estimates of $398.91 million. During the same period last year, the firm earned $2.60 earnings per share. The business’s revenue was up 16.4% compared to the same quarter last year. On average, analysts anticipate that Jazz Pharmaceuticals plc – will post $11.10 EPS for the current year.

TRADEMARK VIOLATION NOTICE: This article was posted by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this article on another domain, it was stolen and reposted in violation of US & international trademark and copyright laws. The correct version of this article can be viewed at https://sportsperspectives.com/2017/04/21/jazz-pharmaceuticals-plc-jazz-upgraded-to-buy-by-janney-montgomery-scott-updated.html.

In other news, SVP Paul Treacy sold 884 shares of the company’s stock in a transaction dated Monday, March 6th. The stock was sold at an average price of $131.97, for a total value of $116,661.48. Following the completion of the sale, the senior vice president now owns 18,108 shares of the company’s stock, valued at $2,389,712.76. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Michael Patrick Miller sold 200 shares of the company’s stock in a transaction dated Wednesday, February 15th. The stock was sold at an average price of $134.55, for a total value of $26,910.00. Following the completion of the sale, the senior vice president now directly owns 16,486 shares of the company’s stock, valued at approximately $2,218,191.30. The disclosure for this sale can be found here. Insiders sold 13,942 shares of company stock valued at $2,098,147 in the last ninety days. Company insiders own 3.90% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of JAZZ. Howard Hughes Medical Institute acquired a new position in shares of Jazz Pharmaceuticals plc – during the third quarter worth approximately $112,000. Brave Asset Management Inc increased its position in shares of Jazz Pharmaceuticals plc – by 540.0% in the third quarter. Brave Asset Management Inc now owns 960 shares of the specialty pharmaceutical company’s stock worth $117,000 after buying an additional 810 shares in the last quarter. Daiwa Securities Group Inc. increased its position in shares of Jazz Pharmaceuticals plc – by 10.7% in the third quarter. Daiwa Securities Group Inc. now owns 1,550 shares of the specialty pharmaceutical company’s stock worth $188,000 after buying an additional 150 shares in the last quarter. Mn Services Vermogensbeheer B.V. increased its position in shares of Jazz Pharmaceuticals plc – by 2.4% in the third quarter. Mn Services Vermogensbeheer B.V. now owns 1,557 shares of the specialty pharmaceutical company’s stock worth $189,000 after buying an additional 37 shares in the last quarter. Finally, Bridges Investment Management Inc. acquired a new position in shares of Jazz Pharmaceuticals plc – during the first quarter worth approximately $208,000. 88.56% of the stock is owned by hedge funds and other institutional investors.

About Jazz Pharmaceuticals plc –

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

5 Day Chart for NASDAQ:JAZZ

Receive News & Ratings for Jazz Pharmaceuticals plc - Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals plc - and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply